CD40LG and cancer: Future studies will leverage the oncolytic and immunomodulatory properties of AdV-D24-ICOSL-CD40L in combination with other anticancer drugs complementing the anti-cancer properties, such as adoptive T cell therapy (ACT) and bispecific antibodies (BsAb), in order to maximize treatment against cancer.